Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 17/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 15/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 14/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 14/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 14/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 13/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 13/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 13/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 13/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 12/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8131488 | 1.00 | HDAC8 (1.00) | HDAC8HDAC1HDAC3HDAC2HDAC10 | |
| SCHEMBL16380891 | 0.84 | HDAC8 (0.73) | HDAC8HDAC1HDAC3HDAC2HDAC10 | |
| SCHEMBL4258833 | 0.82 | HDAC8 (1.00) | HDAC8HDAC1HDAC3HDAC2HDAC10 | |
| SCHEMBL18373231 | 0.79 | HDAC1 (1.00) | HDAC8HDAC1HDAC3HDAC2HDAC10 | |
| SCHEMBL3218780 | 0.73 | HDAC8 (1.00) | HDAC8HDAC1HDAC3HDAC2HDAC10 | |
| SCHEMBL3218796 | 0.73 | HDAC8 (1.00) | HDAC8HDAC1HDAC3HDAC2HDAC10 | |
| SCHEMBL1149552 | 0.73 | HDAC3 (0.56) | HDAC8HDAC1HDAC3HDAC2HDAC10 | |
| SCHEMBL28881222 | 0.69 | HDAC8 (0.77) | HDAC8HDAC1HDAC3HDAC2HDAC10 | |
| SCHEMBL5708630 | 0.68 | HDAC1 (0.64) | HDAC8HDAC1HDAC3HDAC2HDAC10 | |
| SCHEMBL28447391 | 0.68 | APP (0.52) | HDAC8HDAC1HDAC3HDAC2HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3048874-B1 | HAPLOID EMBRYOGENESIS | STICHTING WAGENINGEN RES (NL) | 2019-08-07 | — | — | EP | claimed |
| US-12408605-B2 | Haploid embryogenesis | STICHTING WAGENINGEN RESEARCH (NL) | 2025-09-09 | — | — | US | disclosed |
| US-11332716-B2 | Methods and compositions for producing pancreatic beta cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210378193-A1 | HAPLOID EMBRYOGENESIS | STICHTING WAGENINGEN RESEARCH (NL) | 2021-12-09 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-11026381-B2 | Method for producing haploid, dihaploid and doubled haploid plants by isolated microspore culture | VILMORIN & CIE (FR) | 2021-06-08 | — | — | US | disclosed |
| US-10966381-B2 | Haploid embryogenesis | STICHTING WAGENINGEN RESEARCH (NL) | 2021-04-06 | — | — | US | disclosed |
| EP-3024926-B1 | GENERATING DEFINITIVE ENDODERM AND PANCREATIC PROGENITOR CELLS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-3328185-B1 | METHOD FOR PRODUCING HAPLOID, DIHAPLOID AND DOUBLED HAPLOID PLANTS BY ISOLATED MICROSPORE CULTURE | VILMORIN & CIE (FR) | 2020-06-24 | — | — | EP | disclosed |
| EP-3571926-A1 | HAPLOID EMBRYOGENESIS | Stichting Wageningen Research (NL) | 2019-11-27 | — | — | EP | disclosed |
| WO-2009147549-A1 | THERAPY DELIVERY AND MONITORING USING A GENE OF INTEREST-REPORTER FUSION PROTEIN AND OPTICAL IMAGING | KONINKLIJKE PHILIPS ELECTRONICS N. V. (NL) | 2009-12-10 | — | — | WO | disclosed |
| EP-2128259-A1 | Therapy delivery and monitoring using a gene of interest-reporter fusion protein and optical imaging | Koninklijke Philips Electronics N.V. (NL) | 2009-12-02 | — | — | EP | disclosed |
| EP-2120909-A2 | TREATMENTS OF THERAPY-RESISTANT DISEASES COMPRISING DRUG COMBINATIONS | Ordway Research Institute (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090226429-A1 | Antibodies That Immunospecifically Bind to TRAIL Receptors | HUMAN GENOME SCIENCES, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| WO-2008154382-A1 | HDAC INHIBITORS AND HORMONE TARGETED DRUGS FOR THE TREATMENT OF CANCER | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080312199-A1 | Treatments of therapy resistant diseases and drug combinations for treating the same | ORDWAY RESEARCH INSTITUTE, INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080248046-A1 | Using therapeutic mixture comprising agonist/antagonist immunoglobulin, alkylating agents and enzyme inhibitors to treat and prevent cell proliferative and viral disorders | HUMAN GENOME SCIENCES, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080241155-A1 | Death domain containing receptor 4 | HUMAN GENOME SCIENCES, INC. | 2008-10-02 | — | — | US | disclosed |
| WO-2008076447-A2 | TREATMENTS OF THERAPY-RESISTANT DISEASES COMPRISING DRUG COMBINATIONS | ORDWAY RESEARCH INSTITUTE (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20070292411-A1 | Antibodies That Immunospecifically Bind to TRAIL Receptors | HUMAN GENOME SCIENCES, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332716-B2 | Methods and compositions for producing pancreatic beta cells | IAPP, ALPG, AMY2A | HDAC8 4467/4885HDAC1 4012/4885HDAC3 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.